ZNF703 and ovarian carcinoma: Follow-up of 98 patients with ovarian malignant tumors (as of April 30, 2019), and Kaplan-Meier survival analysis showed that the overall survival of ovarian cancer patients with high expression of ZNF703 was shorter than that of patients with low expression of ZNF703 (P = 0.017) (Fig. 1c).